XORTX Therapeutics Finalizes 1:5 Reverse Stock Split to Meet NASDAQ Listing Requirements
XRTX is trading near its 52-week low of $0.364 (6.5% below the low) on light trading volume (0.1× avg).
Summary
XORTX Therapeutics announced the board's approval and effective date for a 1-for-5 reverse stock split, a crucial step to meet NASDAQ's minimum bid price requirement and avoid delisting.
Key Events · Corporate Governance and Compliance · XRTX
-
Board Approves 1:5 Reverse Stock Split
The board of directors has approved a 1-for-5 reverse stock split, reducing outstanding shares from approximately 6.96 million to 1.39 million.
-
NASDAQ Compliance Critical
The consolidation is necessary to meet NASDAQ's minimum $1.00 bid price requirement and a specific condition to trade above $1.00 for 10 days by April 13, 2026.
-
Effective Date Set
The reverse stock split is effective March 27, 2025 (likely a typo, should be 2026), with post-consolidation trading expected to begin on or about March 27, 2026.
-
Follows Shareholder Approval
This action follows shareholder approval for a consolidation of up to 5:1 at the annual meeting on March 24, 2026.
Analysis · XRTX · Life Sciences
This filing confirms the board's approval and effective date for the previously announced 1-for-5 reverse stock split. This action is critical for XORTX Therapeutics to regain compliance with NASDAQ's minimum bid price requirement, especially given the company's current stock price trading near 52-week lows and the recent "going concern" warning disclosed in its 20-F filing on March 20, 2026. While a reverse split is often viewed negatively as it doesn't address underlying business issues, it is a necessary step to maintain the company's listing and access to capital markets. Investors should monitor the stock's performance post-split to see if it can sustain the $1.00 minimum bid price.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XRTX was trading at $0.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7M. The 52-week trading range was $0.36 to $1.41. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.